Viatris (VTRS) FY2024 10-K Annual Report
Viatris (VTRS) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Viatris FY2024 10-K Analysis
Business Overview
- • Core business model focused on pharmaceutical manufacturing, supply chain, and commercial operations with continued divestiture activity
- • Recent divestitures include Biocon Biologics Transaction, OTC products, women’s healthcare, and API business segments emphasized this year
- • Strategic shift driven by multiple high-profile divestitures resulting in reduced total revenues and cash flows versus prior year
- • Equity consideration from Biocon Biologics valued at approx. $1.3 billion on balance sheet as of Dec 31, 2024, with downside protection but limited liquidity
- • New risks from transition service obligations and indemnification agreements increasing operational exposure and potential financial liabilities
Management Discussion & Analysis
- • No revenue or profitability figures reported in provided MD&A excerpt
- • No segment performance data included in given text
- • No cash flow, buyback, dividend, or capex details disclosed
- • Forward-looking outlook or guidance not mentioned in excerpt
- • Focus solely on explaining use and reconciliation of non-GAAP financial measures
Risk Factors
- • FDA warning letter and import alert on Indore, India facility, blocking 11 products from U.S., 2025 revenue impact approx. $500M, earnings impact $385M
- • Exposure to geopolitical conflicts including Russia-Ukraine and Middle East impacting supply chains and economic conditions in Emerging Markets
- • Dependency on Lexicon for clinical and commercial supply of sotagliflozin outside U.S. and Europe under new licensing agreement with upfront $25M payment
- • Competitive risk from generic entry of Amitiza® 24 μg in Japan in December 2025 after patent expiry
- • High development cost and milestone payments up to $2.75B for Idorsia Phase 3 assets with regulatory and clinical trial uncertainties
Viatris FY2024 Key Financial MetricsXBRL
Revenue
$14.7B
▼ -4.5% YoY
Net Income
-$634M
▼ -1259.4% YoY
Gross Margin
38.3%
▼ -357bp YoY
Operating Margin
0.1%
▼ -491bp YoY
Net Margin
-4.3%
▼ -467bp YoY
ROE
-3.4%
▼ -367bp YoY
Total Assets
$41.5B
▼ -13.0% YoY
EPS (Diluted)
$-0.53
▼ -1160.0% YoY
Operating Cash Flow
$2.3B
▼ -17.7% YoY
Source: XBRL data from Viatris FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Viatris Annual Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.